Navigation Links
Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Date:11/20/2007

RICHMOND, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:00 am (ET) on Wednesday, November 28, 2007 at the Piper Jaffray 19th Annual Health Care Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing seq
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
8. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property ... of intellectual property, announced today that the Markman ... in the U.S. District Court for the Northern ... been rescheduled for November 10, 2014.  This hearing ... Court Order setting the Markman date was received ...
(Date:10/1/2014)... Jolla, Calif. (PRWEB) September 30, 2014 ... announced the initial round of grants for the ... an undertaking that aims to develop and revolutionize ... circuit functions of the human brain. This first ... for fiscal year 2014 was allocated to more ...
(Date:10/1/2014)... Centreville, VA (PRWEB) October 01, 2014 ... the Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing ... and regulatory positions at the director level and above ... payers struggling to stay on top of rapid breakthroughs ... a result, many diagnostic companies have been forced to ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... on Custom Medical Devices, SOUTH ORANGE, N.J., Aug. ... -- Vincent J. Capricci, 56, is a former public,school ... avid,hunter, golfer and fisherman. After minor surgery a few ... his ankle joint.,He was out of work for nine ...
... has appointed FBI Supervising Special Agent (Ret.) Dr. Philip Hayden as its ... ... (Business Wire EON) August 18, 2008 -- Dr. Hayden comes to ... Dr. Philip Hayden has spent years involved in many aspects of law ...
... Includes $10 Million in Upfront Fees and Milestones ... INC.,(OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ... agreement under which,Milestone will market Access, proprietary product ... a company recently started by former,executives and sales ...
Cached Biology Technology:FDA Gets Knocked Out in Endotec, Inc. Ruling 2FDA Gets Knocked Out in Endotec, Inc. Ruling 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3
(Date:10/2/2014)... 2014 The global genomics market was valued ... grow at a CAGR of over 12.0% from 2013 ... expansion of genomics applications, and advancements in existing technologies ... to invest in this market. Next Generation Sequencing (NGS) ... a high growth area for the global genomics market. ...
(Date:10/1/2014)... hope to take a healthy salad up a level ... breast cancer in leafy greens. , "In the long ... by eating the salad or making a pill from ... biomedical engineering at Case Western Reserve School of Medicine ... Komen breast cancer organization is funding the research with ...
(Date:10/1/2014)... , October 1, 2014 ... in the life science field  The ... come and go over the years. Some are ... Photon upconversion is a novel detection technology that ... years. Now, finally, this technology is becoming commercially ...
Breaking Biology News(10 mins):Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018 2Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
... Minidizer is a personal desktop unit ideal for ... requirements. , Rotation speed set at 12 ... 80o C , Bottle capacity of four ... 15 ml conical ,plastic bottles , Consistent, ...
Biology Products: